CFON-026

• Target :

  BTK

• Related Pathways :

  Tyrosine Kinase/Adaptors|||Angiogenesis

• Bioactivity :

  CFON-026 is a selective, orally active, non-covalent BTK inhibitor with an IC50 of 0.27 nM. It demonstrates significant antitumor activity against wild-type BTK (TMD8 and REC-1) as well as all clinically relevant BTK resistance mutations (BTKC481S, T474I, L528W, and V416L) . CFON-026 induces complete tumor regression in the TMD8 xenograft mouse model. This compound is applicable for research into hematologic cancers, such as chronic lymphocytic leukemia and Waldenström's macroglobulinemia.

• Smiles :

  NC=1C=2N3C([C@]4(C[C@](NC(=O)CCCCC\C=C\C3=CN1)(CCC4)[H])[H])=NC2C5=CC=C(C(NC6=CC(C#N)=CC=N6)=O)C=C5

• Molecular Formula :

  C33H34N8O2

• Molecular Weight :

  574.68

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2941611-57-8